Oneness Biotech Co., Ltd. is a biotechnology company founded in 2008 that focuses on the research and development of innovative drugs. The company’s therapeutic areas include wound care, chronic skin conditions, immune disorders, metabolic diseases, and small nucleic acid therapeutics. Its core products include FESPIXON, a cream for treating diabetic foot ulcers approved in multiple Asian markets, and Bonvadis, a wound care medical device with regulatory approvals in the United States, the European Union, and other regions. The company’s pipeline includes FB704A, an anti-IL6 monoclonal antibody for rheumatoid arthritis and tumor angiogenesis, and SNS851, a weight-loss drug targeting hepatic mitochondria for metabolic diseases. Oneness Biotech develops these candidates using its proprietary full human antibody library platform and conducts clinical trials in markets such as Australia and the United States.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage onenessbio.com
Sector Healthcare IR page onenessbio.com/investor-relations
Tags
wound care, diabetic foot ulcers, monoclonal antibodies, metabolic diseases, rheumatoid arthritis, small nucleic acids, chronic skin conditions, obesity, liver disease, FESPIXON, Bonvadis, FB704A, SNS851
Press page onenessbio.com/en/news

Metrics

Valuation  
Market cap NT$ 18.918B
Market cap (USD) $ 574.18M
P/E -87.67
PEG —
P/BV 1.91
P/S 135.16
P/OCF -54.74
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -9.2%
ROI -10.1%
ROIC -5.8%
Profit margin -809.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -37.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 129.123M 117.926M 86.783M 1.066B 65.765M 41.605M 13.475M 18.856M 2.587M 5.703M 7.841M 5.479M 4.609M
Net profit -1.045B -1.165B -1.313B 359.975M -403.303M -241.9M -322.206M -235.436M -155.446M -14.257M -93.017M 199.726M 276.253M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 55.6 — — — — — — — — — — — —
P/S 206.34 — — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Oneness Biotech Co., Ltd. (ticker 4743.TWO), listed in Taiwan.

ETFs Holding Oneness Biotech Co., Ltd.

ETF Weight in ETF Shares Market value As of
RCGE 0.48% 338,477 $ 480K Nov 18, 2026
AVSE 0.00% 143 $ 208.87 Nov 16, 2026